
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is an early/clinical stage drug development company with a focus on developing cannabinoid-based formulations for the treatment of Alzheimer’s disease. The company has multiple promising drug candidates and has reported positive interim results from its ongoing trials for the treatment of agitation in Alzheimer’s patients. Its recent change in fiscal year end to align with other major pharmaceutical companies and potential upcoming milestones make it an attractive investment, but risks include liquidity, regulatory approval, and competition in the biotech industry.
Bears say
IGC Pharma is an early/clinical stage drug development company focused on developing novel therapies for Alzheimer's disease. While it has reported positive results in preclinical studies and recently achieved over 70% patient enrollment in its Phase 2 CALMA trial, its current revenue is minimal and its net loss is larger than expected. Furthermore, the company's goal of completing its CALMA trial and releasing its AI beta program in mid-2026 may be ambitious, leading to potential delays and increased risks. Overall, the stock's current valuation may be attractive, but the high risks and uncertainties surrounding the company's pipeline and financials warrant a negative outlook.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares